{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:28:13Z","timestamp":1794544093973,"version":"4.9.1"},"reference-count":45,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1644,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2036.2011.04612.x","type":"journal-article","created":{"date-parts":[[2011,3,4]],"date-time":"2011-03-04T00:33:02Z","timestamp":1299198782000},"page":"987-995","source":"Crossref","is-referenced-by-count":572,"title":["Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease"],"prefix":"10.1111","volume":"33","author":[{"given":"S.","family":"Ben-Horin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,2]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance Infliximab for Crohn\u2019s Disease: the ACCENT 1 randomized trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn\u2019s disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","article-title":"Infliximab dose intensification in Crohn\u2019s disease","volume":"13","author":"Requeiro","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ibd.20329","article-title":"Infliximab dependency in pediatric Crohn\u2019s disease: long-term follow-up of an unselected cohort","volume":"14","author":"de Ridder","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ibd.21328","article-title":"Dosage adjustment during long-term adalimumab treatment for Crohn\u2019s disease: clinical efficacy and pharmacoeconomics","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab pegol in patients with moderate to severe Crohn\u2019s disease and secondary failure to infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2036.2008.03890.x","article-title":"Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England","volume":"29","author":"Russo","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2036.2008.03878.x","article-title":"Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and na\u00efve patients","volume":"29","author":"Swaminath","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of Infliximab is the F(ab\u2019)2 fragment, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1124\/jpet.104.079277","article-title":"Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys","volume":"313","author":"Rojas","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ibd.21491","article-title":"Adherence to adalimumab therapy in Crohn\u2019s disease: a French multicenter experience","volume":"17","author":"Billioud","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB30|cit30","unstructured":"Vermeire S Gabriels F Ballet V et\u00a0al. The effect of dose escalation on trough levels in patients who lost response to infliximab Gut 2010 59 Suppl III A81"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to Infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled Infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.crohns.2008.05.011","article-title":"Management of loss of response to anti-TNF drugs: Change the dose or change the drug?","volume":"2","author":"Van Assche","year":"2008","journal-title":"J Crohns Colitis"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2036.2010.04523.x","article-title":"The efficacy of shortening the dosing interval to once every six weeks in Crohn\u2019s patients losing response to maintenance dose of Infliximab","volume":"33","author":"Kopylov","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in Rheumatoid Arthritis","volume":"46","author":"St. Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2036.2009.04101.x","article-title":"Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab","volume":"30","author":"Ma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1365-2036.2007.03548.x","article-title":"Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn\u2019s disease: a cost-effectiveness analysis","volume":"26","author":"Kaplan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2036.2009.04130.x","article-title":"The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn\u2019s disease after failure of two other anti-TNF antibodies","volume":"31","author":"Allez","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB42|cit42","first-page":"1","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"13","author":"Bendtzen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring Infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomized placebo-controlled trial","volume":"130","author":"L\u00e9mann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04612.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/gut.2008.157339","article-title":"Thiopurines\u2019 delayed-onset of the anti-inflammatory effect: early preservation of immune effector functions followed by eventual memory cell depletion","volume":"58","author":"Ben-Horin","year":"2009","journal-title":"Gut"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04612.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04612.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:05:26Z","timestamp":1625418326000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04612.x"}},"subtitle":["Review: loss of response to anti-TNF in Crohn\u2019s disease"],"short-title":[],"issued":{"date-parts":[[2011,3,2]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04612.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,2]]}}}